ArticleJAMA network open2021
Trends in Patient Volume by Hospital Type and the Association of These Trends With Time to Cancer Treatment Initiation.
Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Regional Variation in Bladder Cancer Clinical Trial Availability in the US.JAMA network open · 2026Article
- Facility Type Predicts Treatment Regimen for Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma.World journal of otorhinolaryngology - head and neck surgery · 2025Article
- Differences in time to treatment and impact on overall survival in adolescents and young adults with Hodgkin lymphoma.Leukemia & lymphoma · 2025Article
- Systematic review on the technology's role in supporting lung cancer patients in the treatment journey.NPJ digital medicine · 2025Article
- Burden of prolonged treatment delay among patients with common cancers in the Philippines.Cancer causes & control : CCC · 2025Article
- Multiple myeloma care, treatment patterns, and treatment durations in academic and community care settings.Future oncology (London, England) · 2025Observational
- Pulmonologists' Attitudes and Role in Precision Medicine Biomarker Testing for Non-Small Cell Lung Cancer.Chest · 2024Article
- The administration of immune checkpoint inhibitors via an elastomeric pump versus conventional intravenous infusion: an economic perspective.BMC health services research · 2024Observational
- Increasing radiation therapy and lower survival for human papillomavirus-related oropharynx cancer associated with a shift to community cancer center care.Journal of the National Cancer Institute · 2024Article
- "Cancer's a demon": a qualitative study of fear and multilevel factors contributing to cancer treatment delays.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study.Annals of surgical oncology · 2023Article
- Organization of Cancer Specialists in US Physician Practices and Health Systems.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Development of a Multilevel Model to Identify Patients at Risk for Delay in Starting Cancer Treatment.JAMA network open · 2023Article
- Survival Outcomes of Ewing Sarcoma and Rhabdomyosarcoma by High- versus Low-Volume Cancer Centres in British Columbia, Canada.Diagnostics (Basel, Switzerland) · 2023Article
- Impact of Cancer Care Regionalization on Patient Volume.Annals of surgical oncology · 2023Article
- Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans.Journal of clinical medicine · 2022Article
- Addressing Challenges and Controversies in the Management of Prostate Cancer with Multidisciplinary Teams.Targeted oncology · 2022Review
- Developing an mHealth App for Empowering Cancer Survivors With Disabilities: Co-design Study.JMIR formative research · 2022Article
- Programmatic Efforts Increase Adoption of Genomic Precision Medicine in Cancer Care in a Community Cancer Center.JCO precision oncology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
Importance: Increasing demand for cancer care may be outpacing the capacity of hospitals to provide timely treatment, particularly at referral centers such as National Cancer Institute (NCI)-designated and academic centers. Whether the rate of patient volume growth has strained hospital capacity to provide timely treatment is unknown. Objective: To evaluate trends in patient volume by hospital type and the association between a hospital's annual patient volume growth and time to treatment initiation (TTI) for patients with cancer. Design, Setting, and Participants: This retrospective, hospital-level, cross-sectional study used longitudinal data from the National Cancer Database from January 1, 2007, to December 31, 2016. Adult patients older than 40 years who had received a diagnosis of 1 of the 10 most common incident cancers and initiated their treatment at a Commission on Cancer-accredited hospital were included. Data were analyzed between December 19, 2019, and March 27, 2020. Exposures: The mean annual rate of patient volume growth at a hospital. Main Outcomes and Measures: The main outcome was TTI, defined as the number of days between diagnosis and the first cancer treatment. The association between a hospital's mean annual rate of patient volume growth and TTI was assessed using a linear mixed-effects model containing a patient volume × time interaction. The mean annual change in TTI over the study period by hospital type was estimated by including a hospital type × time interaction term. Results: The study sample included 4 218 577 patients (mean [SD] age, 65.0 [11.4] years; 56.6% women) treated at 1351 hospitals. From 2007 to 2016, patient volume increased 40% at NCI centers, 25% at academic centers, and 8% at community hospitals. In 2007, the mean TTI was longer at NCI and academic centers than at community hospitals (NCI: 50 days [95% CI, 48-52 days]; academic: 43 days [95% CI, 42-44 days]; community: 37 days [95% CI, 36-37 days]); however, the mean annual increase in TTI was greater at community hospitals (0.56 days; 95% CI, 0.49-0.62 days) than at NCI centers (-0.73 days; 95% CI, -0.95 to -0.51 days) and academic centers (0.14 days; 95% CI, 0.03-0.26 days). An annual volume growth rate of 100 patients, a level observed at less than 1% of hospitals, was associated with a mean increase in TTI of 0.24 days (95% CI, 0.18-0.29 days). Conclusions and Relevance: In this cross-sectional study, from 2007 to 2016, across the studied cancer types, patients increasingly initiated their cancer treatment at NCI and academic centers. Although increases in patient volume at these centers outpaced that at community hospitals, faster growth was not associated with clinically meaningful treatment delays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.